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PURPOSE. We compared macular pigment (MP) measurements using customized heterochro-
matic flicker photometry (Macular Metrics Densitometer) and dual-wavelength fundus
autofluorescence (Heidelberg Spectralis HRA þ OCT MultiColor) in subjects with early age-
related macular degeneration (AMD).
METHODS. Macular pigment was measured in 117 subjects with early AMD (age, 44–88 years)
using the Densitometer and Spectralis, as part of the Central Retinal Enrichment
Supplementation Trial (CREST; ISRCTN13894787). Baseline and 6-month study visits data
were used for the analyses. Agreement was investigated at four different retinal eccentricities,
graphically and using indices of agreement, including Pearson correlation coefficient
(precision), accuracy coefficient, and concordance correlation coefficient (ccc).
RESULTS. Agreement was poor between the Densitometer and Spectralis at all eccentricities, at
baseline (e.g., at 0.258 eccentricity, accuracy ¼ 0.63, precision ¼ 0.35, ccc ¼ 0.22) and at 6
months (e.g., at 0.258 eccentricity, accuracy ¼ 0.52, precision ¼ 0.43, ccc ¼ 0.22).
Agreement between the two devices was significantly greater for males at 0.58 and 1.08 of
eccentricity. At all eccentricities, agreement was unaffected by cataract grade.
CONCLUSIONS. In subjects with early AMD, MP measurements obtained using the Densitometer
and Spectralis are not statistically comparable and should not be used interchangeably in
either the clinical or research setting. Despite this lack of agreement, statistically significant
increases in MP, following 6 months of supplementation with macular carotenoids, were
detected with each device, confirming that these devices are capable of measuring change in
MP within subjects over time. (http://www.controlled-trials.com number, ISRCTN13894787.)
Keywords: macular pigment, customized heterochromatic flicker photometry, fundus
autofluorescence, age-related macular degeneration, concordance, agreement
Macular pigment (MP) is composed of the carotenoids,lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ).1
Macular pigment is found at the macula (the specialized part of
the retina that mediates central vision) between the receptor
axon and inner plexiform layers.2,3 Macular pigment filters
short-wavelength (blue) light and its constituent carotenoids
have antioxidant4,5 and anti-inflammatory properties.6–9 Macu-
lar pigment’s unique anatomic location, blue light filtering
properties, and antioxidant and anti-inflammatory properties
make this pigment important for visual function.10 Macular
pigment (and its constituent carotenoids) may have an
important role in age-related macular degeneration (AMD) by
reducing oxidative stress via its antioxidant properties as well
as limiting the effect of inflammatory mediators in the
pathogenesis of this condition.11 Some studies also have
reported that MP may be lower compared to controls among
persons with glaucoma,12 Alzheimer’s disease (AD),13 and
diabetes,14,15 suggesting that MP could be a useful biomarker
for these conditions, providing a biologically plausible rationale
to investigate whether MP has a role in these pathologies.
Given the importance of MP for visual function in
diseased16–18 and nondiseased retinas,19,20 and the emerging
evidence that MP may be a useful biomarker for AD,21,22
researchers and clinicians must measure MP levels accurately
across different populations. A variety of techniques are
available for measuring MP (and its constituent carotenoids)
and the measurement techniques can be classified broadly as ex
vivo (i.e., outside cell/tissue) and in vivo techniques (i.e., inside
cell/tissue). Ex vivo techniques include high performance
liquid chromatography (HPLC) and microdensitometry. How-
ever, these ex vivo techniques can be performed only in
postmortem eyes. In vivo techniques include physical tech-
niques (e.g., dual-wavelength fundus autofluorescence (2WAF),
fundus reflectometry, and raman spectroscopy) and psycho-
physical techniques (e.g., heterochromatic flicker photometry
[HFP], customized heterochromatic flicker photometry [cHFP],
color matching, and motion photometry), and these methods
are desirable because they can be performed noninvasively in
the living subject. The 2WAF technique also can be used ex
vivo. Of note, however, there remains debate as to which
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device, if any, should be deemed as ‘‘gold standard’’ for
measuring MP. A review of the literature shows that HFP and
cHFP are the most commonly used, but it is important to note
that each device has its own advantages and limitations.
The Heidelberg Spectralis HRAþOCT MultiColor (Heidel-
berg Engineering GmbH, Heidelberg, Germany) is a new,
commercially available device which uses the 2WAF technique
to measure MP, whereas the Macular Densitometer (Macular
Metrics, Corp., Providence, RI, USA) has been available for over
a decade, with over 100 peer-reviewed scientific publications
which have used this device. A previous study from our group
compared MP measurements using the Spectralis to measure-
ments obtained using the Densitometer (which uses cHFP),
and reported good concordance between the results obtained
by the two devices at four different retinal eccentricities.23
However, that previous study was performed in subjects free of
retinal disease with a mean age of 49 6 13 years.23 Therefore,
to our knowledge until now, concordance between the
Spectralis and the Densitometer has not been evaluated
appropriately in the AMD population. The current study was
designed to investigate concordance between these two
devices, and was done as part of the Central Retinal
Enrichment Supplementation Trials (CREST),24 a randomized
double-blind clinical trial designed to investigate the impact of
supplementation with the macular carotenoids (L, Z, and MZ)
on visual function in healthy subjects with low MP and in
subjects with early AMD (the study population used in the
current investigation; CREST AMD [ISRCTN13894787]). We
see this MP measurement concordance study as an important
experiment, as it will inform researchers and clinicians on the
agreement between the devices and emphasize the importance
of not changing the measurement technique when assessing
subjects/patients over time.
METHODS
The design and methodology of the CREST study, including
intervention assignment, has been described in detail previ-
ously.24 For CREST AMD, the population of interest for the
current investigation, the eligibility criteria included early AMD
(one to eight on AREDS 11-step severity scale25 in at least one
eye [the study eye], confirmed by the Moorfields Eye Hospital
Reading Centre [MEHRC], London, UK), best-corrected visual
acuity (BCVA) of 6/12 (20/40) or better, no more than five
diopters spherical equivalence of refraction, no previous
consumption of supplements containing the macular caroten-
oids (L, Z, and/or MZ), no other retinal pathology beyond AMD,
and no diabetes mellitus (by self-report). Ethical approval was
granted by Research Ethics Committee of the Waterford
Institute of Technology (WIT), Waterford, Ireland, and the
Ethics Committee of the European Research Council (ERC).
Written informed consent was obtained from each subject
before study enrollment. The tenets of the Declaration of
Helsinki were followed in the experimental procedures. A
comprehensive clinical assessment, which included MP
measurement using cHFP and 2WAF (see below), was
conducted at the Macular Pigment Research Group (available
in the public domain at www.mprg.ie), Vision Research
Centre, Waterford Institute of Technology, Ireland by the study
investigator (KOA), who was trained in all aspects of the
CREST protocol. All subjects for this investigation were na¨ıve
to the MP measurement protocols and had no previous
experience with any of the tests.
Macular Pigment Measurement
MP Measurement by cHFP. Macular pigment was
measured by cHFP using the Macular Densitometer (Macular
Metrics, Corp.) at 0.258, 0.58, 1.08, and 1.758 of retinal
eccentricity, with a reference point at 78.26 This protocol has
been described in detail previously and has been validated in
AMD subjects by comparing the in vivo spectral absorption
curves from this device to the ex vivo spectral absorption
curves of the macular carotenoids.27 Two wavelengths of light,
one at 458 nm (blue light; wavelength that is well absorbed by
MP) and the other at 550 nm (green light; wavelength that is
not absorbed by MP) are arranged in a stimulus-surround
configuration where the stimulus consists of a target presented
in counterphase flicker (alternating blue to green). The blue
and green alternating lights are inverse-yoked so that when the
blue light is adjusted to be more intense, the green light is
decreased commensurately and vice versa. The radiance of the
blue and green lights are adjusted by turning a dial until the
flicker of the disk stops (null flicker) or it is at a point of
minimal flicker. Thus, null flicker occurs when there is
isoluminance of the blue and green lights.
Before MP measurements, the testing procedure was
explained and the subject’s critical flicker frequency (CFF)
was estimated using a prediction table based on age. Setting
the flicker rate according to an expected optimal for a narrow
null zone helps to minimize the variance in radiance values
obtained during MP measurements at a given retinal eccen-
tricity. If the subject could not reach the null flicker, the CFF
was increased by 1 Hz in a stepwise fashion until null flicker
was perceived. Also, if the subject exhibited a wide variation in
null flicker reading, the CFF was decreased in steps of 1 Hz
until an acceptable null range was achieved. During the test,
subjects were instructed to turn the radiance knob clockwise
or counterclockwise until the flickering stops or it is at a point
of minimal flicker. The starting radiance is alternated, so that
the knob is not always turned in the same direction.
Throughout the testing, subjects were reminded to blink, and
instructions were repeated where necessary. Six measure-
ments at each of the targets (0.258, 0.58, 18, 1.758, and a
reference point at 78) were taken for each subject. The MP
measurement at a specified retinal eccentricity was computed
from the radiance values obtained where the subject reported
null flicker and these radiance values were deemed reliable and
acceptable only when the standard deviation of the MP value
was below 0.1 optical density units (ODU). The log ratio of the
difference in radiance values between the measurement at a
particular retinal eccentricity (0.258, 0.58, 18, 1.758) and the
measurement at 78 yields the MP optical density at the
specified test locus. Data were not obtained from three
(2.6%) subjects because they could not complete the test
reliably.
Pupillary Dilation. Pupils were dilated using a drop each
of 0.5% proxymetacaine hydrochloride, 2.5% phenylephrine
hydrochloride, and 1% tropicamide before performing MP
measurement by 2WAF, retinal photography, and cataract
grading.
MP Measurement by 2WAF. Macular pigment was
measured by 2WAF28–30 using the Spectralis HRAþOCT
MultiColor (Heidelberg Engineering GmbH). This new tech-
nology uses confocal scanning laser ophthalmoscopy imaging
with diode lasers to measure MP.23,31 The 2WAF technique
works on the principle of excitation of fluorophores (primarily
lipofuscin) in the retina and provides a single-pass MP
measurement. Fluorescence is an internal property of certain
molecules (known as fluorophores) which makes them emit
light when excited at certain wavelengths. Lipofuscin is
excited by light between 400 and 590 nm and emits light
between 520 and 800 nm.32,33 The excitation spectrum of
lipofuscin overlaps with the absorption spectrum of MP (400–
550 nm with maximum absorption at 460 nm)2 and this
property is used in the 2WAF technique.
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Before MP measurement, alignment, focus and illumination
are first adjusted in infrared mode. Once the image is
illuminated evenly, the laser mode is switched from infrared
to blue plus green laser light autofluorescence. Focus and
illumination are readjusted for optimal acquisition. The retina
is illuminated simultaneously with two wavelengths of light
(486 nm, which is absorbed by MP, and 518 nm, which is not
well absorbed by MP) to obtain a series of autofluorescence
images within 30 seconds. These images are digitally subtract-
ed to generate MP spatial distribution maps with the reference
set at 78. Macular pigment at 0.238, 0.478, 0.988, and 1.768
retinal eccentricities was recorded. Data were not obtained in
two (1.7%) subjects because one subject found bright lights
unbearable and refused to continue the test, and the other
subject was not able to open the eyes sufficiently for a reliable
measurement to be obtained.
Retinal Photography and AMD Grading
Stereoscopic color fundus photographs (458) were taken in
three retinal photographic fields (optic disc, macula, temporal
to macula) using a Zeiss Visucam 200 (Carl Zeiss Meditec AG,
Jena, Germany). In addition, a monoscopic photograph of the
anterior segment was taken to document any media opacities.
Photographs were transferred to the MEHRC, London, UK via
an encrypted system and were graded in a masked fashion
adhering to the Age-Related Eye Disease Study (AREDS) 11-step
severity scale.25
Cataract Grading
Cataract grading was performed using the Haag-Streit BM 900
slit-lamp biomicroscope (Haag-Streit AG, Koeniz, Switzerland)
adhering to the Lens Opacities Classification System III (LOCS
III)34 within the first year of this study by a trained and certified
grader (KOA).
The degree of nuclear opalescence (NO) and color (NC)
was graded on a scale ranging from 0.1 to 6.9 while cortical (C)
and posterior subcapscular (PSC) opacities were graded on a
scale ranging from 0.1 to 5.9. In addition, pseudophakia versus
cataract in the study eye also was recorded during grading.
Statistical Analysis
One eye (the study eye) of each subject comprised the unit of
analysis. The study eye was chosen by adhering to the
eligibility criteria with particular emphasis on the presence
of early AMD, BCVA of 6/12 (20/40), no more than five diopters
spherical equivalence of refraction and no other retinal
pathology beyond AMD. The study eye could be either the
right or left eye. If both eyes had early AMD, the eye with the
best BCVA was chosen as the study eye. However, if both eyes
had the same BCVA, the right eye was selected. Statistical
analysis was performed using IBM SPSS Statistics for Windows,
version 22.0 (IBM, Armonk, NY). Data analyzed included
baseline and 6-month study visits. We decided to use 6-month
data, in addition to baseline data, for the following reasons: (1)
to investigate whether agreement between the two devices
was the same at two different time points (in other words, is
there better agreement [as determined by agreement indices]
at 6 months in comparison to baseline?); and (2) to investigate
whether the two devices are able to consistently detect
changes in MP following 6 months of supplementation with
the macular carotenoids. Of note, 6-month data should
represent increased MP levels in all subjects, given that all
subjects in CREST AMD were consuming a formulation
containing either 10 mg/day L, 10 mg/day MZ, and 2 mg/day
Z or 10 mg/day L and 2 mg/day Z.24 Uniquely, this allows us to
assess concordance at baseline and at 6 months, and also the
capacity of each device to detect change in MP over time.
Agreement indices, and confidence limits for these indices,
were obtained using the statistical programming language R
code35 supplied with Lin et al.36 Agreement was investigated
graphically using ordinary scatterplots of MP from the two
devices being compared (with line y ¼ x superimposed). In
addition, agreement was assessed using three indices of
agreement (see Appendix): (1) precision, the Pearson correla-
tion coefficient, measures the degree of scatter, with values
close to 1 indicating closeness to the ordinary least squares
regression line (and, hence, little scatter); (2) accuracy,
constructed from the means and standard deviations of the
two variables being compared, with values close to 1
indicating that the two means are close to each other and
that the two standard deviations are close to each other; and
(3) concordance correlation coefficient (ccc), obtained as the
product of the other two coefficients.
The possible effect on agreement of age, sex, AMD, and
cataract, was investigated using a general linear model. Level of
significance was set at P < 0.05 without adjusting for multiple
comparisons.
RESULTS
Table 1 presents the demographic, MP, cataract, and AMD
grades of all subjects included in this report. Agreement indices
between the Densitometer and Spectralis at baseline study visit
are shown in Table 2. The Figure shows the scatterplots of the
TABLE 1. Demographic, Lifestyle, Cataract, and AMD Characteristics of
Subjects Included in This Report
Variable
Age, y, mean 6 SD 64.68 6 9.08
Sex, n (%)
Male 39 (33.7)
Female 78 (66.7)
Cataract, mean 6 SD*
Nuclear opalescence 1.65 6 0.83
Nuclear color 2.40 6 0.95
Cortical 0.84 6 1.03
Posterior subcapsular 0.35 6 0.56
Pseudophakia, n (%)* 6 (5.1)
AMD grades, n (%)
1–3 30 (25.6)
4–5 57 (48.7)
6–8 30 (25.6)
SP_MP, mean 6 SD*
0.23 0.52 6 0.19
0.47 0.44 6 0.17
0.98 0.33 6 0.14
1.76 0.14 6 0.08
DM_MP, mean 6 SD*
0.25 0.75 6 0.26
0.5 0.63 6 0.22
1 0.45 6 0.17
1.75 0.32 6 0.14
Data displayed are mean 6 SD for interval data and percentages for
categorical data. SP_MP, macular pigment at 0.238, 0.478, 0.988, and
1.768 eccentricity using dual-wavelength fundus autofluorescence
(Heidelberg Spectralis HRA þ OCT MultiColor); DM_MP, macular
pigment at 0.258, 0.58, 1.08 and 1.758 eccentricity using customized
heterochromatic flicker photometry (cHFP; Macular Metrics Densi-
tometer). Age-related macular degeneration grades are based on the
AREDS 11-step severity scale.
* n „ 117 as certain tests/measures could not be obtained.
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MP values at 0.258, 0.508, 1.008, and 1.758 eccentricity, with the
line y ¼ x superimposed. Table 2 and the Figure exhibit poor
agreement between the two devices at all eccentricites.
We investigated the effect on agreement of other study
variables, using general linear models with difference in
measured MP (Densitometer–Spectralis) as dependent vari-
able.
Effect of Age and Sex on Agreement Between the
Two Devices
The effect of age and sex on agreement at the four retinal
eccentricities was investigated using a general linear model.
Agreement was unaffected by age (P > 0.05, for all
eccentricities). However, disagreement between the two
TABLE 2. Agreement Indices for MP Measurements Using the Macular
Densitometer and the Heidelberg Spectralis HRAþOCT Multicolor at
Baseline (V1)
Measure ccc Precision Accuracy
0.25 0.22 (0.12) 0.35 (0.21) 0.63 (0.54)
0.5 0.27 (0.17) 0.41 (0.27) 0.67 (0.58)
1.0 0.20 (0.08) 0.26 (0.11) 0.76 (0.66)
1.75 0.08 (0.01) 0.19 (0.04) 0.41 (0.34)
For each coefficient, the 95% lower confidence limit is shown in
parentheses.
FIGURE. Scatterplots with the line y ¼ x superimposed comparing macular pigment measurements using the Macular Densitometer (DM) to the
Heidelberg Spectralis HRAþOCT Multicolor (SP) at baseline (V1).
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devices was significantly greater for males at 0.58 (P ¼ 0.025)
and 1.08 (P ¼ 0.007) of eccentricity.
Effect of Cataract Grade and Pseudophakia on
Agreement Between the Two Devices
The effect of cataract grades (NO, NC, C, PSC) on agreement
between the two devices was investigated using a general
linear model, independently and after controlling for age and
sex. Agreement was unaffected by grade of cataract in all our
analyses (P > 0.05). The effect of pseudophakia on agreement
also was investigated using a general linear model, but the
nonsignificant result in this case may be due to lack of
statistical power, as there were few cases of pseudophakia in
this study (see Table 1).
Effect of AMD Grade on Agreement
The effect of AMD grades (as defined on the AREDS 11-step
severity scale) on agreement between the two devices was
investigated using a general linear model, independently and
after controlling for age and sex. We combined AMD grades 1
to 3 and 4 to 8 for this analysis. Agreement was unaffected by
AMD grade in all general linear model analyses controlling for
age and sex (P > 0.05, for all). Not controlling for age and sex,
there is a relationship between AMD grade and disagreement at
1.08 eccentricity (P¼ 0.019), but greater disagreement occurs
in the low-risk (1–3) AMD category (Table 3).
Agreement Within Study Subgroups
These findings (on the relationship between agreement and
other study variables) are summarized in Table 3, using simple
binary classifications of age and cataract grades. The P values
displayed in Table 3 are from the independent samples t-test,
and there is one more statistically significant result than from
the earlier general linear model analysis; however, greater
disagreement in Table 3 is found among the under-65s, not the
older subjects.
Is Agreement Different Between Study Visits, That
Is, Baseline (V1) and 6 Months (V2)?
The agreement indices at baseline and 6 months were similar;
that is, there still is, at 6 months, poor agreement between the
Densitometer and Spectralis at all retinal eccentricities (e.g.,
baseline at 0.258 eccentricity, accuracy ¼ 0.63, precision ¼
0.35, ccc ¼ 0.22; 6 months at 0.258 eccentricity, accuracy ¼
0.52, precision ¼ 0.43, ccc ¼ 0.22).
Measuring Change in MP Over Time
Despite these differences between MP measured by the two
devices, when we look at change in MP over time (baseline
versus 6-month study visit), using a paired t-test, the
conclusion is the same; that is, on average, MP increases
significantly after 6 months of supplementation, whichever
TABLE 3. Subgroup Analyses of the Average Differences in MP Measurements Using the Macular Densitometer and the Heidelberg Spectralis
HRAþOCT Multicolor at Baseline (V1)
Subgroups n
MP at 0.25 MP at 0.5 MP at 1.0 MP at 1.75
Av. Diff.,
DM-SP Sig.
Av. Diff.,
DM-SP Sig.
Av. Diff.,
DM-SP Sig.
Av. Diff.,
DM-SP Sig.
Age, y
<65 61 0.25 0.302 0.22 0.093 0.16 0.029 0.19 0.161
‡65 56 0.20 0.15 0.08 0.15
Sex
Male 36 0.27 0.164 0.25 0.025 0.19 0.007 0.20 0.112
Female 76 0.20 0.16 0.09 0.15
AMD grades
1–3 28 0.26 0.356 0.23 0.248 0.19 0.019 0.21 0.111
4–8 84 0.21 0.17 0.10 0.16
Cataract grades*
Nuclear opalescence
<2.5 83 0.24 0.805 0.20 0.844 0.13 0.834 0.18 0.529
‡2.5 7 0.27 0.22 0.11 0.21
Nuclear Color
<2.5 55 0.23 0.621 0.18 0.329 0.12 0.829 0.16 0.177
‡2.5 35 0.26 0.23 0.13 0.21
Cortical
<1.0 60 0.25 0.678 0.22 0.360 0.13 0.727 0.18 0.830
‡1.0 30 0.23 0.17 0.12 0.18
Posterior subcapsular
<0.5 74 0.25 0.688 0.21 0.557 0.14 0.135 0.19 0.053
‡0.5 16 0.22 0.17 0.06 0.11
Age-related macular degeneration grades are based on the AREDS 11-step severity scale. n, number; Av. Diff., DM-SP, average differences in
macular pigment between the Densitometer (Macular Metrics Densitometer) and the Spectralis (Heidelberg Spectralis HRAþOCT MultiColor); Sig.,
level of significance set at standard P < 0.05 and obtained using the Independent samples t-test.
* n „ 117 as certain tests/measures could not be obtained.
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device is used. For example, mean MP at 0.258 eccentricity
measured on the Densitometer increases from 0.76 to 0.85
(12%) after 6 months (P < 0.001), and mean MP at 0.238
eccentricity measured on Spectralis increases from 0.52 to 0.60
(15%; P < 0.001).
DISCUSSION
In the present study, we evaluated the concordance of two MP
measuring devices (Densitometer and Spectralis) in subjects
with early AMD, and assessed the ability of these devices to
detect change in MP over time. In brief, the results of this
experiment suggested that MP measurement on both devices
are not statistically comparable. Assessing the data (see Fig.), it
appears that the Spectralis tends to undervalue MP measure-
ments when compared to the Densitometer. Moreover, this
poor agreement was not only present at baseline (before
supplementation with the macular carotenoids), but it also was
seen at 6 months following supplementation with the macular
carotenoids. However, it is important to point out that both
devices were capable of detecting changes within subjects
following supplementation with formulations containing the
macular carotenoids.
Of note, the Spectralis device used in this study has been
compared previously (by our group) with the Densitometer in
normal healthy subjects.23 In contrast to the current study,
concordance in subjects free of retinal disease was good.23
Possible reasons for the lack of agreement in the current
study are discussed. Firstly, we studied factors that we believe
may contribute to the poor concordance we identified
between the two devices in the early AMD population. The
variables examined included age, sex, cataract, and AMD grade,
and the analysis was done with general linear models (i.e.,
controlling for other variables) and based on binary versions of
each variable (older and younger, lower and higher risk of
AMD, and so forth). Of note, we found that only sex was
associated consistently with disagreement, at 0.58 and 1.08
eccentricities, with greater disagreement between devices for
male subjects. Age and AMD grades were related to disagree-
ment at 1.08 eccentricity, but only in the simplified binary
analysis (Table 3), and in both cases the finding was
counterintuitive, with younger and lower-risk subjects exhib-
iting greater disagreement. Given that we did not adjust for
multiple testing in this study, these reported significant
differences in agreement (for age, sex, and AMD status) should
be treated circumspectly: they may be the result of Type I
errors.
Of note, MP measurement by cHFP has been shown to be
unaffected by cataracts.37,38 However, it may be surprising that
cataract grade did not explain, at least in part, the lack of
agreement we observed between the two devices, given that
MP measurements by fundus autofluorescence have been
reported previously to be affected by cataracts.39,40 It is
important to note, however, that these previous studies, testing
the impact of cataract on MP measurement using fundus
autofluorescence, used different hardware and software to that
used by the Spectralis. Also, in our study, cataract grading was
conducted within the first year of the study, rather than at
baseline, and it is possible, but unlikely, that this may have
influenced our results. Also, it is important to point out that
the level of cataract in our study population was not severe
(e.g., mean NO 1.65; see Table 1), and it is likely that if cataract
is to impact on MP measurement when using fundus
autofluorescence, that this would be directly related to severity
grade of cataract.39,40 Finally, and most importantly, this study
was not designed to investigate the impact of cataract on
Spectralis 2WAF MP measurement. Indeed, a study sufficiently
powered with appropriate design to investigate the influence
of cataract on Spectralis 2WAF MP measurement would involve
MP measurements before and after cataract surgery, and this
precise experiment currently is underway at our research
center.
Fundamentally, the two devices work on different princi-
ples to obtain measurements of MP, with many different
assumptions inherent in each device. For example, cHFP
requires subjects to follow instructions and to make decisions
to obtain MP readings, whereas the 2WAF method does not
require subjects’ responses or decision-making to obtain MP
readings. The subject simply is required to fixate on an internal
target within the system for circa 30 seconds. Therefore, MP is
measured quickly using the Spectralis, and subject fatigue is
not an issue, whereas with the Densitometer, MP measurement
takes circa 30 minutes to obtain MP data at four different
retinal eccentricities. During cHFP, Troxler’s fading may be
induced when viewing the target at the peripheral reference
locus (78 eccentricity), which is a limitation of this technique.
The Spectralis, however, does require pupil dilation, and some
subjects do find the bright lights used in the Spectralis
uncomfortable. Nevertheless, the Spectralis is a class 1 laser
device, which complies with all applicable international
standards with respect to safety. Interestingly, the poor
concordance between the devices also was seen at 6 months
following supplementation with the macular carotenoids,
ruling out any possible learning effect with MP measurement
using either device. The lack of concordance may be
explained, at least in part, by the following assumptions of
the 2WAF method: (1) no fluorophores anterior to MP, which
cannot be compensated for by digital subtraction of the two
autofluorescence images, and (2) the type and composition of
fluorophores is assumed to be constant.28,31,41 The assumption
that lipofuscin is equally distributed has been suggested to be
compensated by the use of two wavelengths.28,31
Despite the lack of agreement between the two devices,
statistically significant increases in MP, following 6 months of
supplementation with macular carotenoids, were recorded
using each device. This finding suggests that, for longitudinal
analyses, if the requirement is to detect change over time, both
devices are capable of detecting such change (i.e., following
supplementation with the macular carotenoids). An important
finding from our study is that it is not appropriate to switch
between devices when measuring MP in the same subjects
over time. For example, mean MP at 0.258 eccentricity, in our
study, was 0.76 ODU on the Densitometer at baseline, whereas
at 6 months mean MP at 0.238 eccentricity was 0.60 ODU on
the Spectralis. Comparison of these two results (baseline for
Densitometer and 6 months for Spectralis) would suggest a
decrease of 21% in average MP after 6 months of macular
carotenoid supplementation in AMD subjects, which clearly is
not the case, as a significant and comparable increase was seen
with each instrument in subjects over time (12% at 0.258 for
Densitometer and 15% at 0.238 for Spectralis).
Each device, therefore, may be suited to a given population,
and perhaps more appropriate for a particular research setting.
It is important that each device is underpinned by its
normative database, given the current diversity of MP research,
and the need to measure MP accurately in the research and
clinic setting. In summary, for clinical or research purposes, it
is advisable that the same device be used for baseline and
follow-up visits within a given study.
The strengths of this study include the following: (1) MP
measurements were conducted in a relatively large sample (n¼
117) of subjects with early AMD at two time points (baseline
and 6 months); (2) assessment of AMD morphology was
performed by an accredited reading center in a masked
fashion; (3) cataract grading was conducted by a trained and
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certified LOCS III grader; (4) subjects were na¨ıve to both tests,
thereby limiting potential confounding attributable to subject
bias; and (5) one trained examiner conducted MP measure-
ments on both devices; therefore, eliminating interexaminer
bias and variability. The main limitation of this study is that
cataract grades were obtained within the first year of the study
rather than at baseline.
In conclusion, specific MP values obtained using the
Spectralis are not comparable to MP values obtained using
the Densitometer in subjects with early AMD. These two
devices should not, for AMD subjects, be used interchangeably
in the clinical or research settings, but each device is capable
of reliably detecting and quantifying change in MP following
supplementation with MP’s constituent carotenoids. Accord-
ingly, it is advisable that the same device be used within a given
study. Furthermore, each of these two devices should be
underpinned by its respective and separate normative data-
base.
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APPENDIX: EXPLANATION OF AGREEMENT INDICES
Notation: Variables X and Y, means Mean(X) and Mean(Y),
standard deviations SD(X) and SD(Y), and covariance Cov(X,Y).
Precision ¼ CovðX;Y Þ
SDðXÞ * SDðY Þ
ð1Þ
Precision is the ordinary Pearson correlation coefficient,
and measures the degree of scatter in the (X,Y) plot around the
best-fitting regression line.
Accuracy ¼ 2
wþ 1
w
þ v2 ; ð2Þ
where
w ¼ SDðXÞ
SDðY Þ and v ¼
MeanðY Þ MeanðXÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SDðXÞ * SDðY Þ
p :
Accuracy will be close to 1 if the two means are close in
value and the two standard deviations are close in value.
Concordance ¼ Precision * Accuracy ð3Þ
Concordance will be close to 1 if precision and accuracy are
both close to 1. Whereas the Pearson correlation coefficient
measures degree of scatter around the least squares regression
line, the ccc measures degree of scatter around the line y¼ x,
and for this reason is a better measure of agreement.
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